RenovaCare, Inc. (RCAR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RenovaCare, Inc. (RCAR) trades at $0.00 with AI Score 48/100 (Grade C). RenovaCare, Inc. is a development-stage biotech company focused on autologous cellular therapies for medical and aesthetic applications. Market cap: $8,735, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for RCAR: RCAR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RCAR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RCAR: the 1 perspectives are evenly split.
How is this calculated? →RenovaCare, Inc. (RCAR) Healthcare & Pipeline Overview
RenovaCare, Inc., operating in the biotechnology sector, is focused on developing and commercializing autologous cellular therapies, primarily the CellMist System and SkinGun technology, for skin regeneration. As a development-stage company, RenovaCare aims to address unmet needs in medical and aesthetic applications through innovative cell-based solutions.
What Is the Investment Thesis for RCAR?
RenovaCare, Inc. presents a high-risk, high-reward investment opportunity characteristic of development-stage biotechnology companies. The core value driver is the successful commercialization of the CellMist System and SkinGun technology. Key catalysts include positive clinical trial results demonstrating efficacy in burn treatment and wound healing. The company's strategic collaboration with StemCell Systems GmbH could accelerate development and expand the application of its technologies. However, the company faces significant risks, including regulatory hurdles, limited financial resources, and competition from established players in the regenerative medicine field. The small market capitalization and OTC listing introduce additional volatility and liquidity concerns. The company's success is contingent upon securing regulatory approvals, demonstrating clinical efficacy, and achieving market acceptance, all of which are subject to considerable uncertainty.
Based on FMP financials and quantitative analysis
RCAR Key Highlights
- RenovaCare is a development-stage biotech company focused on autologous cellular therapies.
- The company's core technology includes the CellMist System and SkinGun for skin regeneration.
- RenovaCare has a strategic collaboration with StemCell Systems GmbH for stem cell research.
- The company operates with a small team of 1 employee, indicating a lean operational structure.
- RenovaCare trades on the OTC market, which can present liquidity and volatility considerations.
Who Are RCAR's Competitors?
RCAR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RCAR's Key Strengths?
- Proprietary CellMist System and SkinGun technology.
- Autologous cell therapy minimizes immune rejection.
- Potential for improved outcomes in burn treatment and wound healing.
- Strategic collaboration with StemCell Systems GmbH.
What Are RCAR's Weaknesses?
- Development-stage company with limited revenue.
- Small team and limited financial resources.
- Reliance on successful clinical trials and regulatory approvals.
- OTC listing introduces liquidity and volatility concerns.
What Could Drive RCAR Stock Higher?
- Clinical trial results for CellMist System in burn treatment.
- Regulatory submissions for SkinGun device.
- Strategic collaboration with StemCell Systems GmbH for stem cell research.
- Development of new applications for autologous cell therapies.
- Pursuit of partnerships and licensing agreements.
What Are the Key Risks for RCAR?
- Negative return on equity (-94.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and delays in obtaining approvals.
- Uncertainty surrounding clinical trial outcomes.
- Competition from established biotech and pharmaceutical companies.
- Limited financial resources and reliance on external funding.
- Risk of technological obsolescence.
What Are the Growth Opportunities for RCAR?
- Expansion into Burn Treatment Market: RenovaCare's CellMist System and SkinGun technology hold significant potential in the burn treatment market. According to the American Burn Association, approximately 486,000 people receive medical treatment for burns annually in the U.S. The company's autologous cell therapy approach could offer improved outcomes and reduced scarring compared to traditional skin grafting methods. Successful clinical trials and regulatory approvals in this area could drive substantial revenue growth for RenovaCare, with a potential market size in the hundreds of millions of dollars annually.
- Application in Wound Healing: Chronic wounds, such as diabetic ulcers and pressure sores, represent a significant unmet medical need. RenovaCare's technology could be adapted for wound healing applications, offering a novel approach to stimulate tissue regeneration and accelerate healing. The global wound care market is projected to reach $22 billion by 2026, presenting a substantial growth opportunity for RenovaCare. Clinical trials demonstrating efficacy in wound healing could open up a new market segment and drive revenue diversification.
- Strategic Partnerships and Licensing Agreements: RenovaCare can leverage strategic partnerships and licensing agreements to expand its reach and accelerate commercialization. Collaborating with established medical device companies or pharmaceutical firms could provide access to broader distribution networks and regulatory expertise. Licensing its technology to other companies for specific applications or geographic regions could generate revenue streams and reduce the financial burden of commercialization. These partnerships could be formed within the next 2-3 years.
- Expansion into Aesthetic Applications: The aesthetic medicine market is a rapidly growing sector driven by increasing demand for non-invasive and minimally invasive cosmetic procedures. RenovaCare's technology could be adapted for aesthetic applications, such as scar revision, wrinkle reduction, and skin rejuvenation. The global aesthetic medicine market is projected to reach $125 billion by 2030. Entering this market could provide RenovaCare with a high-margin revenue stream and diversify its product portfolio. This expansion could begin within the next 3-5 years, following successful clinical trials in medical applications.
- International Expansion: RenovaCare can pursue international expansion to tap into new markets and diversify its revenue streams. Europe, Asia, and Latin America represent significant growth opportunities for regenerative medicine technologies. Securing regulatory approvals in these regions and establishing distribution partnerships could drive international sales and increase the company's global footprint. This expansion could be phased in over the next 5-7 years, starting with key markets in Europe and Asia.
What Opportunities Does RCAR Have?
- Expansion into burn treatment and wound healing markets.
- Application in aesthetic medicine.
- Strategic partnerships and licensing agreements.
- International expansion into new markets.
What Threats Does RCAR Face?
- Competition from established biotech and pharmaceutical companies.
- Regulatory hurdles and delays.
- Uncertainty surrounding clinical trial outcomes.
- Risk of technological obsolescence.
What Are RCAR's Competitive Advantages?
- Proprietary CellMist System technology.
- Patents protecting its autologous cell therapy approach.
- Strategic collaboration with StemCell Systems GmbH.
- First-mover advantage in autologous skin regeneration.
What Does RCAR Do?
RenovaCare, Inc., formerly known as Janus Resources, Inc., was renamed in January 2014 to reflect its focus on regenerative medicine. The company is dedicated to the research, development, and commercialization of autologous cellular therapies. These therapies utilize a patient's own cells to regenerate tissues, primarily targeting medical and aesthetic applications. RenovaCare's core technology revolves around the CellMist System, a proprietary method for isolating and preparing skin cells for regenerative purposes. Complementing this system is the SkinGun, a device designed to deliver these cells to the treatment area. Based in Scottsdale, Arizona, RenovaCare operates with a small team, emphasizing strategic collaborations to advance its technology. A key partnership is with StemCell Systems GmbH, focusing on the isolation and spraying of self-donated stem cells for tissue and organ regeneration. RenovaCare's business model centers on developing and patenting its autologous cell therapies, with the long-term goal of commercializing these technologies for burn treatment, wound healing, and aesthetic procedures. The company's success hinges on navigating regulatory approvals, demonstrating clinical efficacy, and securing market adoption for its innovative cell-based solutions.
What Products and Services Does RCAR Offer?
- Develops CellMist System for isolating skin cells.
- Creates SkinGun device for delivering cells to treatment areas.
- Focuses on autologous cellular therapies.
- Targets medical applications like burn treatment.
- Aims for aesthetic applications such as scar revision.
- Collaborates with StemCell Systems GmbH for stem cell research.
How Does RCAR Make Money?
- Develops and patents autologous cell therapies.
- Seeks regulatory approvals for its technologies.
- Aims to commercialize technologies for burn treatment and wound healing.
- Potentially licenses technology to other companies.
What Industry Does RCAR Operate In?
RenovaCare operates within the regenerative medicine sector, a rapidly growing field focused on developing therapies to repair or replace damaged tissues and organs. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in cell biology and tissue engineering. The competitive landscape includes established biotech and pharmaceutical companies, as well as smaller, innovative players. RenovaCare aims to differentiate itself through its autologous cell therapy approach, which minimizes the risk of immune rejection. The company's success depends on navigating regulatory pathways, demonstrating clinical efficacy, and securing market share in a competitive environment.
Who Are RCAR's Key Customers?
- Hospitals and burn centers.
- Dermatologists and plastic surgeons.
- Patients requiring skin regeneration therapies.
RCAR Valuation & Market Position
With a 9K market cap, RenovaCare, Inc. sits in the micro-cap segment of the market. Relative to its peer group, RCAR's quantitative score of 48/100 is below the peer average of 76/100.
Net buyingInsider Activity
The most recent 12 insider filings for RenovaCare, Inc. break down as 4 sales and 8 purchases. On net that is roughly 7.7M shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.
F-Score 1/9Financial Health
RenovaCare, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE -95%Key Financial Metrics
Return on equity for RenovaCare, Inc. stands at -94.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 2.59 indicates the company holds enough short-term assets to cover its near-term obligations.
RCAR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- RenovaCare's insider activity suggests confidence; recent purchases could signal belief in future growth.
- Community sentiment shows growing optimism around RenovaCare's regenerative technology, potentially driving positive market perception.
- Bullish community views highlight the potential for SkinGun technology to disrupt traditional burn treatment methods.
- Market perception is improving due to increased awareness of RenovaCare's innovative approach to skin regeneration, similar to early enthusiasm surrounding novel biotech solutions.
Bear Case
- Lack of substantial revenue generation raises concerns about long-term viability; reminiscent of early-stage biotech companies facing funding challenges.
- Bearish community views question the scalability and commercialization potential of SkinGun technology, citing regulatory hurdles.
- Recent market developments indicate increased competition in the regenerative medicine space, potentially impacting RenovaCare's market share.
- Limited adoption of SkinGun technology in major burn centers creates uncertainty about its widespread acceptance, echoing challenges faced by niche medical devices.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RCAR Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Thursday
· Dec 12, 2019
RCAR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RCAR.
Price Targets
Wall Street price target analysis for RCAR.
RCAR MoonshotScore
What does this score mean?
The MoonshotScore rates RCAR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Harmel S. Rayat
Managing
Harmel S. Rayat serves as the managing person for RenovaCare, Inc. Information regarding Mr. Rayat's detailed career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive background profile cannot be constructed. However, his current role indicates leadership responsibility for the company's strategic direction and operations.
Track Record: Due to the limited information available, a detailed track record of Mr. Rayat's achievements and strategic decisions at RenovaCare, Inc. cannot be provided. His tenure and key milestones under his leadership remain unknown based on the provided data.
RCAR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that RenovaCare, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, and may be subject to greater regulatory scrutiny. Investing in OTC Other stocks carries significant risks due to the lack of transparency and potential for fraud or manipulation. Compared to NYSE or NASDAQ listings, OTC Other stocks have far less stringent listing requirements, resulting in a higher concentration of speculative and unproven companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volumes and liquidity.
- Greater price volatility and susceptibility to manipulation.
- Potential for delisting or suspension of trading.
- Higher risk of fraud or misrepresentation.
- Verify the company's registration and compliance with regulatory requirements.
- Obtain and review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal proceedings against the company.
- Company's focus on developing innovative autologous cell therapies.
- Strategic collaboration with StemCell Systems GmbH.
- Patents protecting its technology.
- Company's history of operating since its founding.
Common Questions About RCAR (Healthcare)
What does RenovaCare, Inc. do?
RenovaCare, Inc. is a development-stage biotechnology company focused on creating and commercializing autologous cellular therapies for medical and aesthetic applications. Their primary focus is the CellMist System, a technology for isolating and preparing a patient's own skin cells, and the SkinGun, a device for delivering these cells to damaged areas. The goal is to regenerate skin tissue for burn treatment, wound healing, and aesthetic procedures, offering a potential alternative to traditional skin grafting.
What are the main risks for RCAR?
RenovaCare, Inc. faces several significant risks inherent to development-stage biotech companies. These include the uncertainty of clinical trial outcomes, the potential for regulatory delays or rejection, competition from established players with greater resources, the need for substantial capital to fund research and development, and the risk of technological obsolescence. As an OTC-listed company, RCAR also faces liquidity risks and limited financial disclosure, adding to the overall investment risk profile.
What are the key factors to evaluate for RCAR?
RenovaCare, Inc. (RCAR) holds an AI score of 48/100 (low). Not financial advice.
How frequently does RCAR data refresh on this page?
RCAR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RCAR's recent stock price performance?
RenovaCare, Inc. (RCAR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary CellMist System and SkinGun technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RCAR overvalued or undervalued right now?
Valuing RenovaCare, Inc. (RCAR) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RCAR?
Before investing in RenovaCare, Inc. (RCAR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding RCAR to a portfolio?
Key strength of RenovaCare, Inc. (RCAR): Proprietary CellMist System and SkinGun technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Development-stage company with inherent uncertainties.